Volume 15, Number 6—June 2009
Dispatch
Methicillin-Resistant Staphylococcus aureus USA300 Clone in Long-Term Care Facility
Table
Analysis of MRSA clones obtained in a long-term care facility, San Francisco, California, USA, 1997–2006*
Clonal group | Antimicrobial drug resistance, % |
Specimen source, % |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Ery | Cli | Cip | Sxt | Gen | Tet | SST | Respiratory tract | Urine | Blood† | ||
USA100 (n = 299) | 96.2 | 84.9 | 95.9 | 3.3 | 16.9 | 2.6 | 22.7 | 36.4 | 35.1 | 5.8 | |
USA300 (n = 182) | 87.8 | 15.0 | 79.4 | 0.6 | 6.1 | 13.2 | 64.3 | 18.1 | 10.4 | 7.1 | |
USA500 (n = 82) | 84.7 | 27.8 | 71.7 | 28.2 | 20.8 | 6.0 | 30.5 | 28 | 31.7 | 9.8 | |
LFT (n = 98) | 87.3 | 65.6 | 62.8 | 10.9 | 13.4 | 7.8 | 37.2 | 26.6 | 26.6 | 9.6 | |
All MRSA (n = 744) | 91.8 | 64.6 | 87.0 | 7.1 | 21.6 | 5.1 | 32.7 | 25.1 | 23.1 | 6.3 |
*MRSA, methicillin-resistant Staphylococcus aureus; Ery, erythromycin; Cli, clindamycin; Cip, ciprofloxacin; Sxt, trimethoprim-sulfamethozazole; Gen, gentamicin; Tet, tetracycline; SST, skin and skin structure; LFT, low frequency types.
†Blood and other typically sterile sites.